Acurx Pharmaceuticals Aktie

Acurx reported an adjusted loss of $0.53 per share for Q2 2026, beating the analyst estimate of $0.57. Cash rose to $10.7 million, G&A expenses fell 29%, while R&D spending increased to support the Ibezapolstat program. The stock fell about 2.5% premarket as investors weighed ongoing cash burn, the need for additional financing for the Phase III IBZ‑ASPIRE study, and uncertainty until potential approval. Management is preparing the PATHFINDER study and says further discussions with the FDA after completing additional clinical work are possible, but funding for the large Phase III is not yet secured. » Más en de.investing.com

The FDA indicated in a Type C meeting that a marketing application for Ibezapolstat from Acurx could be considered on the basis of a single successful phase 3 study (IBZ-ASPIRE), subject to the totality of clinical data and supporting evidence. The agency stressed the decision would depend on the strength of efficacy, consistency and generalizability to the U.S. population, as well as phase 2 data. Acurx is starting the open-label phase 2 study IBZ-PATHFINDER in recurrent CDI and can initiate the international phase 3 trial once funding is secured; Ibezapolstat has Fast-Track and QIDP status. » Más en de.investing.com

Acurx Pharmaceuticals is expected to report results for the past quarter on August 14, 2026. Three analysts expect an average earnings per share of -$0.377 versus -$1.890 a year earlier. One analyst forecasts revenue of $0.0 million for the quarter and for the year. For the current fiscal year, three analysts see an average loss of -$1.653 per share versus -$5.320 in the prior year. » Más en finanzen.net